Article PDF first page preview

First page of Determining the cut-off value of the MASCC Score to predict mortality in hospitalized febrile neutropenic patients: A decade-long single-center retrospective cohort study

Introduction: Febrile neutropenia [FN] is linked to significant morbidity and mortality in cancer patients. Therefore, our study aims to determine the cut-off value of the MASCC Score to predict mortality in hospitalized FN patients. Methods: We included 354 hospitalized cancer patients, divided into two groups: the mortality group [n=116] and the survival group [n=238]. We defined risk factors of all-cause mortality according to Cox regression model. The optimal cut-off value for MASCC score was found using Youden's index. Results: The 30-day, 60-day, and 90-day mortality rates were 25.1% [n=89], 30.2% [n=107], and 32.7% [n=116], respectively. Having a hematological malignancy, advence age, comorbidities, higher levels of C-reactive protein and procalctonin on admission, profound neutropenia and a lower MASCC score were statistically different in the mortality group compared to the survival group. The only independent risk factor was the MASCC score to predict all-cause mortality according to the multivariate Cox regression models. A MASCC score below 17 showed a sensitivity of 83.6% and a specificity of 94.1% for predicting all-cause mortality in hospitalized FN patients. Conclusions: In this cohort study, we showed 30,60 and 90-day mortality rates of hospitalized patients and determined the risk factors. We supported that the MASCC score was an independent risk factor for predicting mortality in hospitalized FN patients. We contributed to the literature by establishing a threshold value for the MASCC score, below 17, showing notably high sensitivity and specificity for predicting all-cause mortality in FN patients.

Journal Section:
Clinical Study
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.